现在素是一种重定位的GPR119激动剂,通过抑制MST1-Foxo3a信号通路来改善NAFPD中的线粒和β细胞功能
Chenglei Zhang1,2, Jiarui Li1, Lijuan Wang1,3
1School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, China.
Cell proliferation
|October 16, 2024
概括
泰拉索林是一种已识别的GPR119激动剂,通过促进粒和抑制MST1-Foxo3a通路来增强胰腺β细胞功能. 这种药物重新使用显示出对非酒精性脂肪胰腺疾病 (NAFPD) 治疗的希望.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 非酒精性脂肪胰腺疾病 (NAFPD) 与胰腺β细胞功能障碍有关.
- 目前正在研究GPR119激动剂是否有保护β细胞功能的潜力.
研究的目的:
- 使用药物重新定位来选GPR119激动剂.
- 探索GPR119激动剂在NAFPD中增强β细胞功能的分子机制.
主要方法:
- 在MIN6细胞和高脂肪饮食中的GPR119淘汰小鼠中建立了NAFPD模型.
- 选了GPR119激动剂,识别了Tarazosin.
- 评估了泰拉索因对β细胞功能,MST1-Foxo3a通路和线粒细胞衰变的影响.
主要成果:
- 现在激活了GPR119,增加了cAMP和ATP,从而增强了胰岛素分泌.
- 现在osin改善了NAFPD小鼠的葡萄糖水平,肥胖和β细胞功能.
- 现在抑制了MST1-Foxo3a,促进了线粒体,并恢复了β细胞中的线粒体健康.
结论:
- 泰拉索辛激活GPR119以增强细胞和减轻通过MST1-Foxo3a通路在NAFPD中的β细胞功能障碍.
- 现在osin对于NAFPD患者,特别是高血压患者来说是一个潜在的治疗剂.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
505
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
12.8K
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:30Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
01:24Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301